Hosking Partners LLP Has $18.07 Million Stock Position in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Hosking Partners LLP trimmed its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 11.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 54,992 shares of the medical research company's stock after selling 7,118 shares during the period. Hosking Partners LLP owned approximately 0.20% of Bio-Rad Laboratories worth $18,065,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Van ECK Associates Corp raised its stake in shares of Bio-Rad Laboratories by 97.8% in the third quarter. Van ECK Associates Corp now owns 1,303,752 shares of the medical research company's stock valued at $436,861,000 after purchasing an additional 644,530 shares in the last quarter. Point72 Asset Management L.P. bought a new stake in Bio-Rad Laboratories in the 3rd quarter valued at $83,681,000. Wedge Capital Management L L P NC acquired a new position in shares of Bio-Rad Laboratories in the 4th quarter valued at $28,740,000. Mawer Investment Management Ltd. lifted its holdings in shares of Bio-Rad Laboratories by 63.0% during the 3rd quarter. Mawer Investment Management Ltd. now owns 217,885 shares of the medical research company's stock worth $72,900,000 after acquiring an additional 84,237 shares during the period. Finally, Proficio Capital Partners LLC acquired a new stake in shares of Bio-Rad Laboratories during the 4th quarter valued at about $9,820,000. 65.24% of the stock is owned by institutional investors and hedge funds.

Bio-Rad Laboratories Price Performance

Shares of NYSE:BIO traded down $5.29 during midday trading on Tuesday, reaching $251.16. The company's stock had a trading volume of 289,568 shares, compared to its average volume of 231,954. The business's fifty day simple moving average is $325.57 and its 200-day simple moving average is $332.16. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.48 and a quick ratio of 4.85. Bio-Rad Laboratories, Inc. has a fifty-two week low of $248.22 and a fifty-two week high of $387.99. The company has a market capitalization of $7.04 billion, a P/E ratio of -3.86 and a beta of 0.90.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The medical research company reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.86 by $0.04. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. As a group, equities research analysts expect that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently issued reports on BIO shares. Royal Bank of Canada reissued an "outperform" rating and issued a $481.00 price target on shares of Bio-Rad Laboratories in a research report on Tuesday, January 14th. StockNews.com cut Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a report on Monday, February 17th. Finally, Wells Fargo & Company cut their target price on Bio-Rad Laboratories from $360.00 to $345.00 and set an "equal weight" rating for the company in a research report on Wednesday, February 12th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to data from MarketBeat.com, Bio-Rad Laboratories currently has a consensus rating of "Moderate Buy" and a consensus target price of $395.20.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.